The exchange offer provides a tax-efficient path for MDT shareholders to gain direct exposure to MiniMed at a discount. Monitor the final exchange ratio announcement (expected Oct 8) and subscription level — oversubscription would fully separate MiniMed, while undersubscription triggers alternative divestiture. The 7% discount may attract arbitrage activity, but the offer is voluntary and no action is needed for non-participants.
Price Chart
Executive Summary
Medtronic launched an exchange offer to split off at least 80.1% of MiniMed Group (its former Diabetes business) to MDT shareholders. Shareholders can exchange MDT shares for MMED shares at a 7% discount (~$107.53 of MMED stock per $100 of MDT stock tendered), with the offer expiring October 9, 2026. This completes the separation of MiniMed following its March 2026 IPO, allowing Medtronic to refocus capital on Cardiovascular, Neuroscience, and Surgical portfolios.
Key Financial Metrics
Key Facts
- Medtronic launched an exchange offer to split off at least 80.1% of MiniMed Group (Nasdaq: MMED) to MDT shareholders.
- Shareholders can exchange MDT ordinary shares for MMED common stock at a 7% discount, subject to an upper limit of 4.5939 MMED shares per MDT share.
- If the upper limit is not in effect, tendering shareholders are expected to receive ~$107.53 of MMED stock for every $100 of MDT stock tendered.
- Medtronic currently owns ~90% of MiniMed (252,813,348 shares) and is offering up to 225,361,295 MMED shares in the exchange.
- If oversubscribed, Medtronic intends to exchange all remaining 27,452,053 MMED shares; if undersubscribed, it will divest remaining shares via spin-off, split-off, or debt-for-equity exchange.
- Conditions include at least 112,680,647 MMED shares being issued and a tax-free opinion from counsel.
- The exchange offer expires October 9, 2026, with the final exchange ratio announced by October 8, 2026.
- Goldman Sachs and BofA Securities are dealer managers.
Financial Impact
Exchange offer at ~7% discount to MDT; ~$107.53 of MMED per $100 of MDT tendered. Medtronic owns ~90% of MiniMed (252.8M shares).
Risk Factors
- Exchange offer may not meet minimum subscription condition (112.68M MMED shares)
- Tax-free treatment depends on receipt of favorable opinion of counsel
- Undersubscription could lead to alternative divestiture methods with uncertain terms
- MiniMed's performance as an independent company carries execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001628280-26-061674 |
| Document: 0001628280-26-061674-index-headers.html | 0001628280-26-061674 |
| Document: 0001628280-26-061674-index.html | 0001628280-26-061674 |
| Document: 0001628280-26-061674.txt | 0001628280-26-061674 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | Press Release | $92.60 $89.30 | ▼ −3.56% | ▼ −6.13% | $87.01 (−6.03%) |
Sep 15, 2026 16d ago | 425 | $92.60 $89.30 | ▼ −3.56% | ▼ −6.13% | $87.01 (−6.03%) |
Sep 14, 2026 17d ago | 425 | $93.75 $90.77 | ▼ −3.18% | ▼ −5.29% | $87.01 (−7.18%) |
Sep 14, 2026 18d ago | 425 | $93.80 $91.75 | ▼ −2.19% | ▼ −2.29% | $87.01 (−7.23%) |
Sep 14, 2026 18d ago | 425 | $93.80 $91.75 | ▼ −2.19% | ▼ −2.29% | $87.01 (−7.23%) |
Sep 1, 2026 4w ago | Press Release | $92.03 $91.89 | ▼ −0.15% | ▼ −0.23% | $87.01 (−5.45%) |
Sep 1, 2026 4w ago | 8-K | $92.04 $91.89 | ▼ −0.16% | ▼ −0.24% | $87.01 (−5.46%) |
Sep 1, 2026 4w ago | Press Release | $92.04 $91.89 | ▼ −0.16% | ▼ −0.24% | $87.01 (−5.46%) |
Aug 31, 2026 4w ago | Court Ruling | $90.65 $92.39 | ▲ +1.92% | ▲ +2.06% | $87.01 (−4.01%) |
Aug 20, 2026 6w ago | Press Release | $93.35 $91.15 | ▼ −2.36% | ▼ −2.83% | $87.01 (−6.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access